GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iBio Inc (NAS:IBIO) » Definitions » EV-to-FCF

iBio (IBIO) EV-to-FCF : -2.93 (As of Mar. 17, 2025)


View and export this data going back to 2008. Start your Free Trial

What is iBio EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, iBio's Enterprise Value is $47.15 Mil. iBio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $-16.09 Mil. Therefore, iBio's EV-to-FCF for today is -2.93.

The historical rank and industry rank for iBio's EV-to-FCF or its related term are showing as below:

IBIO' s EV-to-FCF Range Over the Past 10 Years
Min: -51.57   Med: -2.5   Max: -0.2
Current: -2.93

During the past 13 years, the highest EV-to-FCF of iBio was -0.20. The lowest was -51.57. And the median was -2.50.

IBIO's EV-to-FCF is ranked worse than
100% of 416 companies
in the Biotechnology industry
Industry Median: 3.79 vs IBIO: -2.93

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-17), iBio's stock price is $5.08. iBio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-2.692. Therefore, iBio's PE Ratio (TTM) for today is At Loss.


iBio EV-to-FCF Historical Data

The historical data trend for iBio's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iBio EV-to-FCF Chart

iBio Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.90 -7.52 -1.01 -0.70 -0.45

iBio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.94 -2.43 -0.45 -0.73 -1.21

Competitive Comparison of iBio's EV-to-FCF

For the Biotechnology subindustry, iBio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iBio's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iBio's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where iBio's EV-to-FCF falls into.



iBio EV-to-FCF Calculation

iBio's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=47.145/-16.092
=-2.93

iBio's current Enterprise Value is $47.15 Mil.
iBio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iBio  (NAS:IBIO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

iBio's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.08/-2.692
=At Loss

iBio's share price for today is $5.08.
iBio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.692.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


iBio EV-to-FCF Related Terms

Thank you for viewing the detailed overview of iBio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


iBio Business Description

Traded in Other Exchanges
N/A
Address
11750 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
Executives
Gary Sender director C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVE, NEW YORK NY 10020
Felipe Duran officer: Interim CFO 8800 HSC PARKWAY, BRYAN TX 77807
William D Clark director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Martin Brenner officer: Chief Scientific Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Evert B. Schimmelpennink director C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Isett Thomas Francis 3rd director, officer: CEO and Executive Chairman C/O IBIO INC. 600 MADISON AVENUE, SUITE 1601, NEW YORK NY 10022
Robert Matthew Lutz officer: See Remarks 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Randy Joe Maddux officer: Chief Operating Officer 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Alexandra Kropotova director RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Linda Washington Armstrong director 8800 HSC PARKWAY, BRYAN TX 77807
John Delta officer: Principal Accounting Officer 8800 HSC PARKWAY, BRYAN TX 77807
Eastern Capital Ltd 10 percent owner 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Robert L Erwin officer: President C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
James P. Mullaney officer: Chief Financial Officer C/O IBIO, INC., 600 MADISON AVE., SUITE 1601, NEW YORK NY 10022
Carl Desantis 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431